In this study, we performed a retrospective analysis to directly compare the clinical efficacy of crizotinib with platinum‐pemetrexed chemotherapy as initial treatment in advanced ROS1+NSCLC patients. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.